(-0.78%) 4 971.88 points
(0.42%) 37 934 points
(-1.81%) 15 319 points
(0.60%) $83.23
(-0.40%) $1.750
(0.50%) $2 409.90
(1.50%) $28.81
(-1.27%) $942.40
(-0.02%) $0.939
(-0.05%) $11.04
(0.54%) $0.808
(-0.89%) $93.06
@ $14.47
Issued: 18 Apr 2024 @ 12:50
Return: -6.64%
Previous signal: Apr 18 - 09:43
Previous signal:
Return: 1.69 %
Live Chart Being Loaded With Signals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases...
Stats | |
---|---|
Today's Volume | 2.10M |
Average Volume | 3.54M |
Market Cap | 2.09B |
EPS | $0 ( 2024-02-28 ) |
Next earnings date | ( $0 ) 2024-04-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 150.06 |
ATR14 | $0.780 (5.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
2024-02-14 | Power Sean A | Buy | 0 | |
2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
INSIDER POWER |
---|
83.80 |
Last 94 transactions |
Buy: 12 977 390 | Sell: 1 920 924 |
Volume Correlation
TG Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
LWAC | 0.972 |
PUCK | 0.963 |
SCAQ | 0.956 |
NVCN | 0.954 |
ALSA | 0.952 |
KALV | 0.952 |
HERAU | 0.951 |
TWLV | 0.951 |
SY | 0.951 |
NVSA | 0.951 |
10 Most Negative Correlations | |
---|---|
AMGN | -0.942 |
NAKD | -0.939 |
STAB | -0.936 |
TUEM | -0.935 |
LGMK | -0.934 |
PROC | -0.933 |
ORPH | -0.932 |
AHPI | -0.931 |
PCSA | -0.928 |
DBGI | -0.92 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
TG Therapeutics Inc Correlation - Currency/Commodity
TG Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $233.66M |
Gross Profit: | $219.11M (93.77 %) |
EPS: | $0.0893 |
Q4 | 2023 |
Revenue: | $43.97M |
Gross Profit: | $36.03M (81.93 %) |
EPS: | $-0.100 |
Q3 | 2023 |
Revenue: | $165.82M |
Gross Profit: | $162.31M (97.88 %) |
EPS: | $0.800 |
Q2 | 2023 |
Revenue: | $16.07M |
Gross Profit: | $14.16M (88.11 %) |
EPS: | $-0.340 |
Financial Reports:
No articles found.
TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators